Ocugen, Inc. announced today that the first patient has been dosed in the OCU200 Phase 1 clinical trial for diabetic macular edema (DME). OCU200 is a novel integrin-targeting biologic, a recombinant fusion protein consisting of tumstatin and transferrin. This milestone marks the initiation of human studies for this promising candidate.
The OCU200 Phase 1 clinical trial is designed as a multicenter, open-label, dose-escalation study to assess drug safety via intravitreal injection across three cohorts. All subjects will receive two intravitreal injections six weeks apart, with patient follow-up extending up to three months after the last injection. OCU200 has the potential to address the 30-40% of DME patients who do not respond to current anti-VEGF therapies.
OCU200's unique mechanism of action, binding tumstatin to integrin receptors, aims to reduce vascular permeability, inflammation, and neovascularization. The company intends to pursue OCU200 as a first-line therapy for DME, diabetic retinopathy (DR), and wet age-related macular degeneration (wet AMD), conditions affecting approximately 12 million people in the United States.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.